Health
US Tariffs Will Raise Drug Prices for Patients, Sandoz CEO Says
- Trump decisions seen likely to worsen supply instability
- CEO sees ‘little point’ in increasing investment in the US
This article is for subscribers only.
The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of the world’s largest makers of generic medicines.
Most generics and biosimilars in the US contain ingredients made elsewhere or are produced entirely abroad, which will hit consumers immediately, Richard Saynor, the chief executive officer of Sandoz Group AG, said in an interview with Bloomberg TV.